Clinical failure of a product linked to Ionis Pharmaceuticals shifts financial focus onto Spinraza royalties.
2 reports, 1 independent
Updated Sep 10
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Clinical failure of a product linked to Ionis Pharmaceuticals shifts financial focus onto Spinraza royalties.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company